LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

CytoSorbents Corp

Fechado

SetorSaúde

0.87 6.1

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.82

Máximo

0.9

Indicadores-chave

By Trading Economics

Rendimento

-5.5M

-7.9M

Vendas

538K

9.2M

EPS

-0.144

Margem de lucro

-86.158

Funcionários

149

EBITDA

-4.6M

-8.5M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+20.48% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-7.9M

54M

Abertura anterior

-5.23

Fecho anterior

0.87

Sentimento de Notícias

By Acuity

38%

62%

130 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de mai. de 2025, 22:52 UTC

Ganhos
Grandes Movimentos do Mercado

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 de mai. de 2025, 20:37 UTC

Principais Notícias
Ganhos

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 de mai. de 2025, 00:00 UTC

Conversa de Mercado

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 de mai. de 2025, 23:47 UTC

Conversa de Mercado

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 de mai. de 2025, 23:38 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de mai. de 2025, 23:38 UTC

Conversa de Mercado

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 de mai. de 2025, 23:14 UTC

Principais Notícias

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 de mai. de 2025, 22:46 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 de mai. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 de mai. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 de mai. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 de mai. de 2025, 21:58 UTC

Ganhos

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 de mai. de 2025, 21:24 UTC

Ganhos

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 de mai. de 2025, 20:56 UTC

Conversa de Mercado

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 de mai. de 2025, 20:54 UTC

Conversa de Mercado
Ganhos

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 de mai. de 2025, 20:54 UTC

Ganhos

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 de mai. de 2025, 20:51 UTC

Ganhos

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

15 de mai. de 2025, 20:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 de mai. de 2025, 20:50 UTC

Ganhos

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 de mai. de 2025, 20:26 UTC

Principais Notícias

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 de mai. de 2025, 20:25 UTC

Ganhos

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

20.48% parte superior

Previsão para 12 meses

Média 1 USD  20.48%

Máximo 1 USD

Mínimo 1 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

0

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.705 / 0.771Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

130 / 382 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.